Physician profile
Eric L Cottrill
NPI 1659368850
$3,238.44
in general payments reported to CMS, 2019-2025
16 companies · $195 in 2025
The $195 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $516 · 2020: $445 · 2021: $500 · 2022: $401 · 2023: $698 · 2024: $483 · 2025: $195.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,212 · Gift: $164.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,212.24 |
| Gift | $163.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $683.36 | 2019-2025 | Skyrizi, Rinvoq |
| Braintree Laboratories, INC. | $607.57 | 2019-2023 | Sutab, Suflave |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $563.47 | 2019-2025 | Xifaxan, Trulance, Relistor |
| Takeda Pharmaceuticals U.S.A., INC. | $544.64 | 2019-2023 | Gattex |
| Gilead Sciences, INC. | $370.37 | 2019-2025 | |
| Janssen Biotech, INC. | $194.67 | 2022-2024 | Stelara, Simponi, Remicade |
| Pfizer INC. | $53.08 | 2024-2025 | |
| Phathom Pharmaceuticals, INC. | $51.90 | 2024-2025 | Voquezna |
| Merck Sharp & Dohme LLC | $41.01 | 2019-2021 | |
| Madrigal Pharmaceuticals | $27.91 | 2025 | Rezdiffra |
| Genzyme Corporation | $23.67 | 2023 | |
| Ferring Pharmaceuticals INC. | $16.78 | 2019 | |
| Alfasigma USA, INC. | $16.55 | 2020 | |
| Intra-Sana Laboratories | $16.31 | 2024 | Glycate, Reltone 400 Mg, Reltone 200 Mg |
| Celgene Corporation | $14.41 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Covidien Lp | $12.74 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Cottrill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.